Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]

AI in multiple myeloma: Recent findings and opportunities

Prof Anant Madabhushi - Emory University, Atlanta, USA

AI in multiple myeloma: Recent findings and opportunities ( Prof Anant Madabhushi - Emory University, Atlanta, USA )

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Optimising immunoglobulin dosing can enhance patient outcomes in multiple...

Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )

Oncologists' perspectives and practices on minimal residual disease testing in...

Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma ( Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA )

The need for improved healthcare infrastructure for extranodal NK/T-cell...

Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala

The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America ( Dr Fabiola Valvert - INCAN, Guatemala City, Guatemala )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

High-fibre dietary intervention in precursor plasma cell disorders improves...

Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Lack of benefit of auto-HCT in MCL patients in first complete remission with...

Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

More from ecancer